Parkinson's disease, Ozempic

Drug Similar to Ozempic Failed to Treat Parkinson’s Disease in a Trial
The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other conditions with newer weight-loss drugs.
Why Did a GLP-1 Receptor Agonist Fail This Parkinson's Trial?
The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients. Weekly injections of the GLP-1 receptor agonist exenatide (Byetta, Bydureon) did not slow Parkinson's disease progression or improve symptoms, the phase III Exenatide-PD3 trial showed.
Diabetes drug similar to Ozempic showed no benefits for patients with Parkinson’s disease
A drug for treating diabetes similar to popular weight-loss medicines such as Ozempic did not show any benefits for people with Parkinson’s disease, according to a new study. Researchers conducted a double-blind,
Ozempic-Type Drug Fails To Slow Parkinson’s, Study Finds
I wouldn’t do another study like this unless you learn what is the target,” Dr. David Standaert, a Parkinson’s researcher at the University of Alabama at Birmingham, told
FDA OKs New Wearable Treatment for Parkinson's Disease
The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced Parkinson's disease, Supernus Pharmaceuticals announced on Tuesday. The wearable device is the first subcutaneous apomorphine infusion device for Parkinson's and provides continuous treatment during the day, Supernus noted.
GLP-1 drug fails to slow Parkinson's: Study
A final-stage study has found that exenatide, a GLP-1 drug used to treat Type 2 diabetes, showed no benefit in slowing the progression of Parkinson's disease. The 96-week trial, published in The Lancet,

Daniel Barenboim, Parkinson's disease

Medscape1h
Despite Early Promise GLP-1 Disappoints in Parkinson’s Disease
Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...
U.S. FDA approves Supernus' drug-device combination for Parkinson's disease
The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals' drug-device combination to treat ...
FDA approves wearable infusion device for advanced Parkinson disease
The U.S. Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only ...
Rolling Out7d
A breakthrough in Parkinson’s disease detection
AI-powered blood test detects Parkinson's disease years before symptoms appear, revolutionizing early diagnosis and treatment ...
Healio1d
GLP-1 does not slow Parkinson’s disease progression in phase 3 study
Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...
Ozzy Osbourne Can No Longer Walk Due to Parkinson’s Ahead of Final Show with Black Sabbath
Sharon Osbourne gave an update on how Parkinson’s disease has impacted husband Ozzy Osbourne’s legs as the musician prepares ...
Hosted on MSN7h
Ozzy Osbourne's Heartbreaking Health Update: Inside the Rocker's Debilitating Struggle With Parkinson's Disease
What is Ozzy Osbourne's health situation? Ozzy lives with Parkinson's disease, and has had numerous surgeries over the ...
Huntsville biotech firm partnering with Pfizer lands $10 million for Parkinson’s trial
A Huntsville-based biotechnology company has secured $10 million in funding to begin the trial of a new way to deliver medication to advanced Parkinson’s disease patients.